| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 68,8 k € | -54.3% | 150,6 k € | +25.6% | 119,9 k € | +191.5% | 41,1 k € | -69.0% | 132,7 k € | +292.0% | 33,9 k € | +20.9% | 28,0 k € | -49.3% | 55,2 k € | +309.1% | -26,4 k € | -157.4% | 46,0 k € | +67.8% | 27,4 k € | +29.0% | 21,3 k € | -32.3% | 31,4 k € | -11.2% | 35,3 k € | +111.5% | 16,7 k € | +18.0% | 14,2 k € | +1009.6% | 1,3 k € | |
| EBITDA | 68,4 k € | -54.4% | 149,9 k € | +25.9% | 119,1 k € | +196.7% | 40,1 k € | -69.6% | 131,9 k € | +303.6% | 32,7 k € | +21.5% | 26,9 k € | -50.9% | 54,7 k € | +304.1% | -26,8 k € | -158.8% | 45,6 k € | +78.2% | 25,6 k € | +28.1% | 20,0 k € | -34.0% | 30,3 k € | -11.8% | 34,3 k € | +138.5% | 14,4 k € | +7.1% | 13,4 k € | +1544.3% | 817,0 € | |
| Operating profit | 51,6 k € | -63.0% | 139,3 k € | +31.1% | 106,2 k € | +284.0% | 27,7 k € | -77.0% | 120,0 k € | +480.5% | 20,7 k € | +37.3% | 15,1 k € | -64.5% | 42,4 k € | +205.6% | -40,1 k € | -220.8% | 33,2 k € | +144.1% | 13,6 k € | +17.2% | 11,6 k € | -47.0% | 21,9 k € | -18.6% | 26,9 k € | +284.7% | 7,0 k € | -47.9% | 13,4 k € | +1544.3% | 817,0 € | |
| Profit/loss | 39,8 k € | -59.5% | 98,3 k € | +35.0% | 72,8 k € | +314.1% | 17,6 k € | -78.8% | 83,0 k € | +582.0% | 12,2 k € | +22.9% | 9,9 k € | -66.1% | 29,3 k € | +171.3% | -41,0 k € | -285.8% | 22,1 k € | +187.0% | 7,7 k € | -48.2% | 14,9 k € | +0.2% | 14,8 k € | -28.4% | 20,7 k € | +1389.9% | 1,4 k € | -84.2% | 8,8 k € | +11064.6% | 79,0 € | |
| Equity | 311,1 k € | -5.7% | 329,8 k € | +21.8% | 270,7 k € | +36.8% | 197,9 k € | -2.2% | 202,4 k € | +69.5% | 119,4 k € | +11.4% | 107,2 k € | +10.2% | 97,3 k € | +43.0% | 68,1 k € | -37.6% | 109,1 k € | +25.4% | 87,0 k € | +9.7% | 79,3 k € | +36.2% | 58,3 k € | +34.2% | 43,4 k € | +91.3% | 22,7 k € | +6.5% | 21,3 k € | +239.2% | 6,3 k € | |
| Total assets | 327,5 k € | -4.5% | 342,8 k € | +10.5% | 310,1 k € | +37.6% | 225,4 k € | -9.1% | 248,1 k € | +59.1% | 155,9 k € | -0.5% | 156,7 k € | +42.0% | 110,4 k € | +27.9% | 86,3 k € | -32.5% | 127,8 k € | +6.8% | 119,7 k € | +16.9% | 102,4 k € | +53.2% | 66,9 k € | +15.5% | 57,9 k € | +9.1% | 53,1 k € | +32.8% | 40,0 k € | +73.8% | 23,0 k € | |
| Cash | 73,4 k € | +17.8% | 62,3 k € | -53.8% | 135,0 k € | -22.9% | 175,2 k € | -14.3% | 204,5 k € | +413.9% | 39,8 k € | -16.1% | 47,4 k € | +14.7% | 41,3 k € | -13.9% | 48,0 k € | -32.7% | 71,4 k € | +20.9% | 59,0 k € | -24.4% | 78,0 k € | +76.0% | 44,4 k € | +135.0% | 18,9 k € | -19.7% | 23,5 k € | -41.2% | 40,0 k € | +73.8% | 23,0 k € | |
| Debts | 16,4 k € | +26.4% | 13,0 k € | -67.1% | 39,4 k € | +43.2% | 27,5 k € | -39.8% | 45,7 k € | +25.2% | 36,5 k € | -26.2% | 49,5 k € | +279.3% | 13,0 k € | -28.4% | 18,2 k € | -2.6% | 18,7 k € | -42.7% | 32,7 k € | +41.4% | 23,1 k € | +168.5% | 8,6 k € | -40.5% | 14,5 k € | -52.4% | 30,4 k € | +62.8% | 18,7 k € | +13.4% | 16,5 k € | |
Private limited company · Meise · incorporated on 28/05/2009
Private limited company profitable and well capitalised. Cash position rising (+17.8%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Raf Schepers Klinische Biologie is a Private limited company incorporated in 2009. Its main activity is: Other human health activities. Its registered office is in Meise.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette